Lung cancer is one of the leading causes of cancer mortality and overall treatment outcomes forlung cancer are still to be considered disappointing despite of development of new medicaltherapeutics on cancer. Cytostatic agents are considered as novel medication in the treatment ofcancer though its benefit is most appropriately assessed through survival end points rather thanthe objective-response end points. We present a case of a lung adenocarcinoma patient whoshowed tumor lesion in patient's two different lung sites. From the day of diagnosis, the tumorlesion stayed with the almost same size with more than 1 year of Allergen-Removed RhusVerniciflua Stokes (A-RVS) based Traditional Korean Medicine treatment without any westernconventional treatment. No significant side effect was noted and the patient maintained goodperformance status throughout the treatment period. We assume A-RVS may have cytostaticeffect on NSCLC patient and our observation justifies further investigation.